Windtree Therapeutics, Inc. (WINT)
WINT Stock Price Chart
Explore Windtree Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze WINT price movements and trends.
WINT Company Profile
Discover essential business fundamentals and corporate details for Windtree Therapeutics, Inc. (WINT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Aug 1995
Employees
14.00
Website
https://windtreetx.comCEO
Jed A. Latkin
Description
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
WINT Financial Timeline
Browse a chronological timeline of Windtree Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 25 Nov 2025
Earnings released on 19 Aug 2025
EPS came in at -$3.06 surpassing the estimated -$99.00 by +96.91%.
Earnings released on 15 May 2025
EPS came in at -$4.63 surpassing the estimated -$180.00 by +97.43%.
Earnings released on 15 Apr 2025
EPS came in at -$99.99 falling short of the estimated -$23.32 by -328.77%, while revenue for the quarter reached $90.00K .
Stock split effective on 21 Feb 2025
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 26 Nov 2024
EPS came in at -$211.50 falling short of the estimated -$2.27 by -9.22K%.
Earnings released on 19 Aug 2024
EPS came in at -$1.05K falling short of the estimated -$405.50 by -157.83%.
Earnings released on 15 May 2024
EPS came in at -$462.50 surpassing the estimated -$495.00 by +6.57%.
Stock split effective on 22 Apr 2024
Shares were split 1 : 18 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 Apr 2024
EPS came in at -$665.47 falling short of the estimated -$0.94 by -70.69K%.
Earnings released on 9 Nov 2023
EPS came in at -$773.38 falling short of the estimated -$0.63 by -122.66K%.
Earnings released on 7 Aug 2023
EPS came in at -$1.47K falling short of the estimated -$0.68 by -216.79K%.
Earnings released on 15 May 2023
EPS came in at -$4.28K falling short of the estimated -$0.56 by -764.29K%.
Earnings released on 3 Apr 2023
EPS came in at -$11.70K falling short of the estimated -$9.45K by -23.81%.
Stock split effective on 24 Feb 2023
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2022
EPS came in at -$5.85K surpassing the estimated -$13.49K by +56.67%.
Earnings released on 11 Aug 2022
EPS came in at -$8.54K falling short of the estimated -$4.95K by -72.73%.
Earnings released on 5 May 2022
EPS came in at -$13.04K surpassing the estimated -$13.94K by +6.45%.
Earnings released on 31 Mar 2022
EPS came in at -$20.68K falling short of the estimated -$14.84K by -39.39%.
Earnings released on 10 Nov 2021
EPS came in at -$13.94K falling short of the estimated -$13.49K by -3.33%.
Earnings released on 5 Aug 2021
EPS came in at -$63.85K falling short of the estimated -$23.38K by -173.08%.
Earnings released on 13 May 2021
EPS came in at -$22.93K falling short of the estimated -$15.00 by -152.78K%.
Earnings released on 29 Mar 2021
EPS came in at -$19.78K falling short of the estimated -$18.88K by -4.76%, while revenue for the quarter reached $23.68M .
Earnings released on 16 Nov 2020
EPS came in at -$24.28K falling short of the estimated -$22.03K by -10.20%.
WINT Stock Performance
Access detailed WINT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.